Valuation : United Therapeutics Corporation

Market Cap 22.64B 19.43B 18.2B 16.65B 31.36B 2,163B 31.48B 215B 84.21B 1,090B 85.01B 83.16B 3,608B P/E 2026 *
20.3x
P/E 2027 * 18.4x
Enterprise Value 19.67B 16.88B 15.81B 14.47B 27.25B 1,879B 27.34B 187B 73.15B 947B 73.85B 72.24B 3,134B EV / Sales 2026 *
6.27x
EV / Sales 2027 * 5.47x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day+2.17%
1 week-0.23%
Current month+1.97%
1 month-0.11%
3 months-8.73%
6 months+4.83%
Current year+8.34%
1 week 508.15
Extreme 508.1541
531.76
1 month 490.8
Extreme 490.8
541.03
Current year 455.63
Extreme 455.63
609.35
1 year 302.19
Extreme 302.19
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 26/06/1996
President 54 26/06/2016
Director of Finance/CFO 58 13/03/2015
Director TitleAgeSince
Director/Board Member 78 01/01/2002
Chairman 71 26/06/1996
Director/Board Member 92 01/01/2002
Date Insider Type Main position Quantity % Market Cap.
8/24/26 A Fiscal year

Chief Executive Officer

28,500 0.0671%
8/21/26 A Fiscal year

Chief Executive Officer

28,500 0.0671%
8/20/26 A Fiscal year

General Counsel

24,900 0.0587%
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%-0.23%+70.72%+130.52% 22.16B
-1.12%-8.14%+59.79%+112.43% 1,060B
-1.57%-2.79%+50.59%+59.86% 651B
-1.81%-2.94%+23.90%+75.98% 465B
-1.17%-0.93%+40.43%+40.43% 365B
-2.00%-1.95%+23.06%+38.92% 300B
-0.98%+0.53%+2.04%+12.13% 258B
-0.76%-1.21%+50.90%+70.45% 238B
-3.18%-1.40%-15.87%-53.79% 210B
+0.52%+0.85%+29.73%+93.68% 184B
Average -0.62%-0.83%+33.53%+58.06% 375.26B
Weighted average by Cap. -0.44%-2.16%+38.75%+66.24%

Financials

2026 *2027 *
Net sales 3.14B 2.69B 2.52B 2.31B 4.35B 300B 4.36B 29.86B 11.67B 151B 11.78B 11.53B 500B 3.44B 2.95B 2.77B 2.53B 4.77B 329B 4.79B 32.75B 12.8B 166B 12.93B 12.64B 549B
Net income 1.2B 1.03B 963M 881M 1.66B 114B 1.66B 11.39B 4.45B 57.66B 4.5B 4.4B 191B 1.32B 1.13B 1.06B 969M 1.83B 126B 1.83B 12.54B 4.9B 63.45B 4.95B 4.84B 210B
Net Debt -2.97B -2.55B -2.39B -2.19B -4.12B -284B -4.13B -28.28B -11.06B -143B -11.16B -10.92B -474B -3.81B -3.27B -3.06B -2.8B -5.27B -364B -5.29B -36.21B -14.15B -183B -14.29B -13.98B -606B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
27/08/26 $527.91 +2.17% 391,004
26/08/26 $516.68 -0.36% 254,780
25/08/26 $518.53 +1.10% 876,497
24/08/26 $512.88 -0.05% 323,887
21/08/26 $513.12 -1.51% 415,573
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
527.91USD
Average target price
664.33USD
Spread / Average Target
+25.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock